INGN · Inogen Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Inogen reported Q2 2026 revenue of $95.1M (up 3%), with international sales up 15% driving growth, while U.S. sales and rentals declined. The company lowered full-year revenue guidance to $355–$361M from $366–$373M but raised full-year adjusted EBITDA guidance to approximately $4.0M (up 48%).
- + International revenue grew 14.8% to $41.3M, marking the 10th consecutive quarter of double-digit international growth.
- + Q2 adjusted EBITDA improved 15.2% to $2.4M and full-year adjusted EBITDA guidance was raised to ~$4.0M (48% growth).
- + Adjusted gross margin expanded 65 bps to 45.6% due to cost improvements and lower warranty expenses.
- + Rove 6 POC launched in Canada, extending international expansion to a market of approximately 2 million COPD patients.
- + Strong liquidity with $106.8M cash and no debt, plus $2.9M positive operating cash flow in Q2.
- − Full-year 2026 revenue guidance was lowered to $355–$361M (from $366–$373M).
- − DTC and rental channels expected to remain under pressure in H2 2026 with rental funnel structurally narrowing.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $2.4M | Three months ended June 30, 2026 filing | — |
| EBITDA (non-GAAP) non-GAAP | -$168K | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INGN
this stock
Inogen Inc
|
$142.25M | -21.6% | +3.9% | — | 5.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INGN | +3.5% | -1.1% | -20.9% | -1.9% | -21.6% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.2% | -1.2% | -33.0% | -1.3% | -33.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.